- Home
- ALLO vs AFRI Comparison
ALLO vs AFRI Comparison
Compare ALLO & AFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- AFRI
- Stock Information
- Founded
- ALLO 2017
- AFRI 1943
- Country
- ALLO United States
- AFRI Gibraltar
- Employees
- ALLO N/A
- AFRI N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- AFRI Packaged Foods
- Sector
- ALLO Health Care
- AFRI Consumer Staples
- Exchange
- ALLO Nasdaq
- AFRI Nasdaq
- Market Cap
- ALLO 252.9M
- AFRI 235.1M
- IPO Year
- ALLO 2018
- AFRI N/A
- Fundamental
- Price
- ALLO $1.21
- AFRI $8.86
- Analyst Decision
- ALLO Buy
- AFRI
- Analyst Count
- ALLO 12
- AFRI 0
- Target Price
- ALLO $8.80
- AFRI N/A
- AVG Volume (30 Days)
- ALLO 2.9M
- AFRI 6.2K
- Earning Date
- ALLO 11-13-2025
- AFRI 01-01-0001
- Dividend Yield
- ALLO N/A
- AFRI N/A
- EPS Growth
- ALLO N/A
- AFRI N/A
- EPS
- ALLO N/A
- AFRI N/A
- Revenue
- ALLO N/A
- AFRI $274,223,000.00
- Revenue This Year
- ALLO N/A
- AFRI N/A
- Revenue Next Year
- ALLO $100.00
- AFRI N/A
- P/E Ratio
- ALLO N/A
- AFRI N/A
- Revenue Growth
- ALLO N/A
- AFRI N/A
- 52 Week Low
- ALLO $0.86
- AFRI $7.47
- 52 Week High
- ALLO $3.78
- AFRI $11.20
- Technical
- Relative Strength Index (RSI)
- ALLO 49.04
- AFRI 52.05
- Support Level
- ALLO $1.21
- AFRI $8.64
- Resistance Level
- ALLO $1.26
- AFRI $9.50
- Average True Range (ATR)
- ALLO 0.08
- AFRI 0.25
- MACD
- ALLO -0.01
- AFRI 0.03
- Stochastic Oscillator
- ALLO 14.18
- AFRI 53.12
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.